Chipscreen(SH:688321) Zheng Quan Zhi Xing·2025-08-22 10:18Core Viewpoint - The legal opinion letter issued by Shanghai Tongli Law Firm confirms that Shenzhen Micron Biotech Co., Ltd. has complied with relevant laws and regulations for its upcoming issuance of A-shares to specific investors, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [2][3][24]. Summary by Sections Legal Framework and Compliance - The legal opinion is based on the Securities Law, Company Law, and other relevant regulations, ensuring that the issuance process adheres to established legal standards [2][3]. - The law firm has verified that all documents provided by the issuer are complete and accurate, and the issuer has the necessary authority to conduct the issuance [2][3]. Issuance Details - The company plans to issue no more than 58,125,305 shares, which will not exceed 30% of the total share capital before the issuance [8][20]. - The issuance will be conducted through a competitive bidding process, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [9][21]. Use of Proceeds - The total amount to be raised from the issuance is capped at 950 million yuan, which will be allocated to innovative drug research and development projects, including the establishment of a new manufacturing base [11][20]. - Prior to the funds being raised, the company may use its own or self-raised funds to initiate project implementation, with a plan to replace these with the raised funds once available [11][13]. Corporate Governance - The board of directors and shareholders have approved all necessary resolutions related to the issuance, ensuring compliance with corporate governance standards [6][14]. - The company has established a clear plan for shareholder returns over the next three years, aligning with the interests of its investors [6][12]. Independence and Control - The company operates independently from its major shareholders and has a complete production and sales system, ensuring no significant adverse impact from related party transactions [25][26]. - The major shareholders and actual controllers have been verified to not have any significant legal issues that could affect the company's operations or investor interests [19][26].